Clinical trial · no report yet · Phase 1
KarMMa-4
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
- NCT04196491 ↗
- Completed
- Celgene
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- bb2121; Fludarabine; Cyclophosphamide; Lenalidomide
- Arms
- Dose Escalation · Experimental
- Enrollment
- 13
- Primary outcomes
- Dose-limiting toxicity (DLT) rates
- Adverse Events (AEs)
- Sponsor
- Celgene
- Start
- May 27, 2020
- Primary completion
- Jun 7, 2023
- Results posted
- No
- Registry record
- NCT04196491 · updated Aug 23, 2023
Publications
linked from the registry- Parmar H, Vesole DH, Biran N. From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma? Cancer J. 2021 May-Jun 01;27(3):190-195. doi: 10.1097/PPO.0000000000000522. PubMed 34549906